Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Serum sickness with furazolidone.

M S Wolfe, A L Moede

    The American Journal of Tropical Medicine and Hygiene
    |July 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Serum sickness cases linked to furazolidone (Furoxona) in Latin America highlight potential adverse drug reactions. Tartrazine (yellow dye number 5) in the medication is a suspected cause, not present in US formulations.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Enzymatic Assays for Studying Intramembrane Proteolysis.

    Methods in enzymology·2017
    Same author

    Discovery of notch-sparing gamma-secretase inhibitors.

    Current Alzheimer research·2010
    Same author

    High Genetic Similarity Among Populations of Phaeosphaeria nodorum Across Wheat Cultivars and Regions in Switzerland.

    Phytopathology·2008
    Same author

    Benefits of organic farming to biodiversity vary among taxa.

    Biology letters·2006
    Same author

    Travel medicine.

    Current opinion in infectious diseases·2006
    Same author

    Notch-Delta signaling is required for spatial patterning and Müller glia differentiation in the zebrafish retina.

    Developmental biology·2005

    Area of Science:

    • Pharmacovigilance
    • Clinical Toxicology
    • Infectious Disease Therapeutics

    Background:

    • Furazolidone (Furoxona) is an antimicrobial agent used to treat giardiasis, particularly in Latin America.
    • Serum sickness is a hypersensitivity reaction typically occurring 1-3 weeks after exposure to a foreign protein or drug.
    • Limited reports exist on furazolidone-induced serum sickness, with none previously documented in the United States.

    Observation:

    • Two cases of serum sickness were observed in patients treated with furazolidone for giardiasis in Latin America.
    • These patients experienced adverse reactions consistent with serum sickness following furazolidone administration.
    • The specific formulation of furazolidone used in Latin America contained tartrazine (yellow dye number 5).

    Findings:

    Related Experiment Videos

    • A potential association between furazolidone use and serum sickness is suggested by these cases.
    • Tartrazine (yellow dye number 5), a component of the Latin American furazolidone formulation, is implicated as a possible causative agent.
    • The absence of tartrazine in current US furazolidone formulations may explain the lack of reported cases in the United States.

    Implications:

    • This suggests that tartrazine may be a trigger for serum sickness in susceptible individuals when present in medications like furazolidone.
    • Healthcare providers, especially in regions where tartrazine-containing furazolidone is used, should be aware of this potential adverse drug reaction.
    • Further investigation into the role of tartrazine as an allergen in drug-induced hypersensitivity reactions is warranted.